Factor Xa Inhibitors Market Surges with Andexanet Alfa and Rivaroxaban Generic Approvals in 2025
According to research analysis, the global Factor Xa inhibitors market, valued at US$ 22.1 billion in 2023, is projected to reach US$ 41.52 billion by 2034, driven by rising cardiovascular diseases. North America leads, while Asia-Pacific shows fastest growth. Key players include Pfizer, Bayer, and AstraZeneca.
Last Updated : 21 April 2026
Category: Therapeutic Area
Insight Code: 5285
Format: PDF / PPT / Excel